igforum.bio / late-breaking-research-angina-is-linked-with-abnormal-heart-blood-flow-in-patients-with-female-pattern-heart-disease - 184789
S
%Begin Late-Breaking Research  Angina is Linked with Abnormal Heart Blood Flow in Patients with Female-Pattern Heart Disease Skip to main content Close 
 Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close 11 November 2015  00:55 AM America/Los_Angeles 
 Late-Breaking Research  Angina is Linked with Abnormal Heart Blood Flow in Patients with Female-Pattern Heart Disease 
 Cedars-Sinai Heart Institute Research Presented Today at American Heart Association Scientific Sessions Shows that Chest Pain is Linked with Abnormal Heart Blood Flow Although Medication Did Not Alleviate Symptoms in Patients with Moderate Coronary Microvascular Dysfunction Contact: Sally Stewart  Email: sally.stewart@cshs.org Los Angeles - Nov.11, 2015 - Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows. The study's results were presented today as a late-breaking trial at the American Heart Association Scientific Sessions in Orlando. The study is published online today by the European Heart Journal and will appear in an upcoming print edition of the journal.
%Begin Late-Breaking Research Angina is Linked with Abnormal Heart Blood Flow in Patients with Female-Pattern Heart Disease Skip to main content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close 11 November 2015 00:55 AM America/Los_Angeles Late-Breaking Research Angina is Linked with Abnormal Heart Blood Flow in Patients with Female-Pattern Heart Disease Cedars-Sinai Heart Institute Research Presented Today at American Heart Association Scientific Sessions Shows that Chest Pain is Linked with Abnormal Heart Blood Flow Although Medication Did Not Alleviate Symptoms in Patients with Moderate Coronary Microvascular Dysfunction Contact: Sally Stewart Email: [email protected] Los Angeles - Nov.11, 2015 - Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows. The study's results were presented today as a late-breaking trial at the American Heart Association Scientific Sessions in Orlando. The study is published online today by the European Heart Journal and will appear in an upcoming print edition of the journal.
thumb_up Like (36)
comment Reply (1)
share Share
visibility 673 views
thumb_up 36 likes
comment 1 replies
C
Chloe Santos 1 minutes ago
The drug, ranolazine, generally is prescribed for patients with angina, an often painful sensation o...
L
The drug, ranolazine, generally is prescribed for patients with angina, an often painful sensation of chest pressure common in coronary artery disease. Coronary artery disease develops when the major blood vessels that supply the heart with blood become damaged, often because cholesterol plaque clogs the heart's major arteries and decreases blood and oxygen flowing to the heart.
The drug, ranolazine, generally is prescribed for patients with angina, an often painful sensation of chest pressure common in coronary artery disease. Coronary artery disease develops when the major blood vessels that supply the heart with blood become damaged, often because cholesterol plaque clogs the heart's major arteries and decreases blood and oxygen flowing to the heart.
thumb_up Like (34)
comment Reply (3)
thumb_up 34 likes
comment 3 replies
L
Luna Park 6 minutes ago
Coronary artery disease typically affects male patients. In women, cholesterol plaque tends to sprea...
L
Luna Park 6 minutes ago
As a result, many women go undiagnosed although they are at high risk for a heart attack. "Most...
E
Coronary artery disease typically affects male patients. In women, cholesterol plaque tends to spread more evenly into thousands of tiny blood vessels that surround the heart muscle. Women with this condition, called coronary microvascular dysfunction, often undergo tests for coronary artery disease, which fail to reveal coronary microvascular dysfunction.
Coronary artery disease typically affects male patients. In women, cholesterol plaque tends to spread more evenly into thousands of tiny blood vessels that surround the heart muscle. Women with this condition, called coronary microvascular dysfunction, often undergo tests for coronary artery disease, which fail to reveal coronary microvascular dysfunction.
thumb_up Like (9)
comment Reply (1)
thumb_up 9 likes
comment 1 replies
M
Madison Singh 7 minutes ago
As a result, many women go undiagnosed although they are at high risk for a heart attack. "Most...
D
As a result, many women go undiagnosed although they are at high risk for a heart attack. "Most standard treatments for heart disease were developed after being tested exclusively on men," said Noel Bairey Merz, MD, director of the Barbra Streisand Women's Heart Center in the Cedars-Sinai Heart Institute.
As a result, many women go undiagnosed although they are at high risk for a heart attack. "Most standard treatments for heart disease were developed after being tested exclusively on men," said Noel Bairey Merz, MD, director of the Barbra Streisand Women's Heart Center in the Cedars-Sinai Heart Institute.
thumb_up Like (36)
comment Reply (0)
thumb_up 36 likes
A
"For too long, physicians treated women's heart disease the same way they treated heart disease in men. We wanted to test if the symptoms experienced in these patients are related to coronary microvascular dysfunction by using a medication known to be effective in chronic angina, to see if this treatment could be helpful to women with microvascular or female-pattern heart disease." Bairey Merz led the double-blinded, placebo-controlled study as part of the National Heart, Lung, and Blood Institutes' Women's Ischemia Syndrome Evaluation (WISE) study, a multi-year, multi-center research initiative aimed at improving diagnosis and developing treatments for microvascular heart disease. In the study conducted at the Cedars-Sinai Heart Institute and at the University of Florida, 128 coronary microvascular dysfunction patients – 96 percent of them women – were given 500 to 1,000 milligrams of ranolazine twice daily for two weeks and a placebo pill daily for two weeks.
"For too long, physicians treated women's heart disease the same way they treated heart disease in men. We wanted to test if the symptoms experienced in these patients are related to coronary microvascular dysfunction by using a medication known to be effective in chronic angina, to see if this treatment could be helpful to women with microvascular or female-pattern heart disease." Bairey Merz led the double-blinded, placebo-controlled study as part of the National Heart, Lung, and Blood Institutes' Women's Ischemia Syndrome Evaluation (WISE) study, a multi-year, multi-center research initiative aimed at improving diagnosis and developing treatments for microvascular heart disease. In the study conducted at the Cedars-Sinai Heart Institute and at the University of Florida, 128 coronary microvascular dysfunction patients – 96 percent of them women – were given 500 to 1,000 milligrams of ranolazine twice daily for two weeks and a placebo pill daily for two weeks.
thumb_up Like (2)
comment Reply (2)
thumb_up 2 likes
comment 2 replies
M
Madison Singh 6 minutes ago
Neither patients nor their physicians knew which pill group patients were assigned at which time. Du...
N
Nathan Chen 9 minutes ago
Results include: Whether taking the medication or taking the placebo, patients experienced no statis...
R
Neither patients nor their physicians knew which pill group patients were assigned at which time. During both investigational segments, the patients were assessed and tested, using the Seattle Angina Questionnaire and a test to measure the blood flow through the heart.
Neither patients nor their physicians knew which pill group patients were assigned at which time. During both investigational segments, the patients were assessed and tested, using the Seattle Angina Questionnaire and a test to measure the blood flow through the heart.
thumb_up Like (19)
comment Reply (0)
thumb_up 19 likes
S
Results include: Whether taking the medication or taking the placebo, patients experienced no statistical difference in angina or blood flow. Change in angina directly correlated with change in heart blood flow. Patients who experienced an improvement in increased blood flow also reported an improvement in angina.
Results include: Whether taking the medication or taking the placebo, patients experienced no statistical difference in angina or blood flow. Change in angina directly correlated with change in heart blood flow. Patients who experienced an improvement in increased blood flow also reported an improvement in angina.
thumb_up Like (36)
comment Reply (2)
thumb_up 36 likes
comment 2 replies
E
Elijah Patel 21 minutes ago
The subgroup of patients with severe coronary microvascular dysfunction had significantly less angin...
L
Lucas Martinez 12 minutes ago
29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Boost...
L
The subgroup of patients with severe coronary microvascular dysfunction had significantly less angina along with improved blood flow through the heart and more satisfying quality of life "Although ranolazine was not effective in the general population of coronary microvascular dysfunction patients, we did find that patients with more severe dysfunction did experience some benefit," Bairey Merz said. "We also were pleased to be able to show that symptoms are related to the blood flow through the heart." The study was supported by the National Heart, Lung, and Blood Institute under award number 5R01HL090957 and by Gilead Sciences, Inc., a biopharmaceutical company that produces ranolazine and markets it under the brand name Ranexa. Share this release Late-Breaking Research  Angina is Linked with Abnormal Heart Blood Flow in Patients with Female-Pattern Heart Disease Share on: Twitter Share on: Facebook Share on: LinkedIn 
 Search Our Newsroom 
 Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) 
 Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept.
The subgroup of patients with severe coronary microvascular dysfunction had significantly less angina along with improved blood flow through the heart and more satisfying quality of life "Although ranolazine was not effective in the general population of coronary microvascular dysfunction patients, we did find that patients with more severe dysfunction did experience some benefit," Bairey Merz said. "We also were pleased to be able to show that symptoms are related to the blood flow through the heart." The study was supported by the National Heart, Lung, and Blood Institute under award number 5R01HL090957 and by Gilead Sciences, Inc., a biopharmaceutical company that produces ranolazine and markets it under the brand name Ranexa. Share this release Late-Breaking Research Angina is Linked with Abnormal Heart Blood Flow in Patients with Female-Pattern Heart Disease Share on: Twitter Share on: Facebook Share on: LinkedIn Search Our Newsroom Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept.
thumb_up Like (41)
comment Reply (1)
thumb_up 41 likes
comment 1 replies
J
James Smith 7 minutes ago
29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Boost...
E
29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster?
29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster?
thumb_up Like (49)
comment Reply (0)
thumb_up 49 likes
L
Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home
Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home
thumb_up Like (18)
comment Reply (3)
thumb_up 18 likes
comment 3 replies
J
Julia Zhang 29 minutes ago
Late-Breaking Research Angina is Linked with Abnormal Heart Blood Flow in Patients with Female-Patt...
L
Luna Park 25 minutes ago
The drug, ranolazine, generally is prescribed for patients with angina, an often painful sensation o...

Write a Reply